SEC Form 4 · accession 0001123292-16-002563
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Diane Myers
Officer — Senior VP-Reg/Quality
Period of report
Aug 1, 2016
Accepted (ET)
Aug 3, 2016 · 2:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 1, 2016 | M | 2,500 | — | A | 2,500 | D | |
| Common Stock | Aug 1, 2016 | F | 940 | $9.70 | D | 1,560 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On August 1, 2016, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to 2,500 performance-based restricted stock units, which were converted into 2,500 shares of common stock on a one-for-one basis.